Taysha Gene Therapies Inc (TSHA NASDAQ) stock market data APIs
$1.76
-0.08(-4.3%)
as of January 2, 2025
Taysha Gene Therapies Inc Financial Data Overview
Price chart is built with
Anychart
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Prev. Close
1.84
Open
1.76
Volume
409 K
High
1.855
Low
1.72
52 wk Range
1.19-4.32
Market Cap
355 M
P/E Ratio
2.746
Shares Outstanding
205 M
Revenue
9 915 K
EPS
-0.0712
Beta
0.414
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Taysha Gene Therapies Inc data using free add-ons & libraries
Get Taysha Gene Therapies Inc Fundamental Data
Taysha Gene Therapies Inc Fundamental data includes:
- Net Revenue: 9 915 K
- EBITDA: -81 154 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-12
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Taysha Gene Therapies Inc News
New
Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?
We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ranks among the best NASDAQ stocks under $5. Job Market ...
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
Taysha Gene Therapies, Inc. DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-b...
3 Growth Stocks That Could Go Parabolic in 2024
The year 2023 was a great one for large cap growth stocks, which outperformed the rest of the market by a wide margin. However, the opposite was true for most small to mid-cap innovation companies, wh...
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
Taysha Gene Therapies, Inc. Initiation of REVEAL pediatric trial in the U.S.broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Rett syndrome MHRA authoriz...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- 100 000+ API requests per day
- EOD Data - All World Extended
- Splits and Dividends
- Fundamental Data
- Bonds Data
- Options Data
- 1000+ currency pairs
- 1000+ cryptocurrency pairs
